Eiger BioPharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Eiger BioPharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 672 %, a 808% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 672 +598 +808% Dec 31, 2023
Q3 2023 233 +166 +246% Sep 30, 2023
Q2 2023 136 +75.3 +123% Jun 30, 2023
Q1 2023 93.8 +37.2 +65.7% Mar 31, 2023
Q4 2022 74 +23.2 +45.7% Dec 31, 2022
Q3 2022 67.3 +20.6 +43.9% Sep 30, 2022
Q2 2022 61.2 +15.5 +34% Jun 30, 2022
Q1 2022 56.6 +5.58 +10.9% Mar 31, 2022
Q4 2021 50.8 -13.4 -20.9% Dec 31, 2021
Q3 2021 46.8 -27.4 -36.9% Sep 30, 2021
Q2 2021 45.7 -35.6 -43.8% Jun 30, 2021
Q1 2021 51.1 -21 -29.2% Mar 31, 2021
Q4 2020 64.3 -4.7 -6.82% Dec 31, 2020
Q3 2020 74.2 +12.3 +20% Sep 30, 2020
Q2 2020 81.3 +15.8 +24.2% Jun 30, 2020
Q1 2020 72.1 +3.34 +4.86% Mar 31, 2020
Q4 2019 69 -1.01 -1.44% Dec 31, 2019
Q3 2019 61.8 -20.9 -25.3% Sep 30, 2019
Q2 2019 65.5 -22 -25.1% Jun 30, 2019
Q1 2019 68.8 -46.7 -40.4% Mar 31, 2019
Q4 2018 70 -23.3 -25% Dec 31, 2018
Q3 2018 82.7 +5.99 +7.81% Sep 30, 2018
Q2 2018 87.4 +42.4 +93.9% Jun 30, 2018
Q1 2018 115 +87.4 +311% Mar 31, 2018
Q4 2017 93.3 +74.2 +389% Dec 31, 2017
Q3 2017 76.7 +58 +311% Sep 30, 2017
Q2 2017 45.1 Jun 30, 2017
Q1 2017 28.1 Mar 31, 2017
Q4 2016 19.1 Dec 31, 2016
Q3 2016 18.7 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.